Cargando…

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment

PURPOSE: Liposarcoma (LPS) represent the largest group of malignant soft tissue tumours comprising a heterogeneous group of subtypes in which the degrees of chemoresistance and radiosensitivity strongly vary. Consequently, it is of utmost interest to establish novel therapeutic regimens based on mol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vay, Christian, Schlünder, Philipp M., Dizdar, Levent, Esposito, Irene, Ghadimi, Markus P. H., Knoefel, Wolfram T., Krieg, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881260/ https://www.ncbi.nlm.nih.gov/pubmed/34860309 http://dx.doi.org/10.1007/s00432-021-03871-5

Ejemplares similares

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
por: Vay, Christian, et al.
Publicado: (2022)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis
por: Krieg, Sarah, et al.
Publicado: (2022)

Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
por: Werner, Thomas A, et al.
Publicado: (2016)

Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
por: Tao, Yan-Fang, et al.
Publicado: (2012)

Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels
por: Sim, Mei Yi, et al.
Publicado: (2017)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells
por: Zhang, Jian, et al.
Publicado: (2016)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
por: Nakamura, Naoto, et al.
Publicado: (2012)

Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues
por: Cheng, Xiao Jiao, et al.
Publicado: (2016)

YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation
por: Chandrasekaran, Arun Pandian, et al.
Publicado: (2020)

Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia
por: Dizdar, Levent, et al.
Publicado: (2016)

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
por: Gholizadeh, Shima, et al.
Publicado: (2018)

YM155, specific survivin inhibitor, can enhance artesunate-induced cytotoxicity in HCT116 colon cancer cells
por: Kim, Eui Tae, et al.
Publicado: (2020)

Survivin and XIAP – two potential biological targets in follicular thyroid carcinoma
por: Werner, Thomas A., et al.
Publicado: (2017)

Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS
por: MINODA, MASAYA, et al.
Publicado: (2015)

A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
por: Guo, Kai, et al.
Publicado: (2015)

YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice
por: Zhao, Nan, et al.
Publicado: (2015)

Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway
por: Sim, Mei Yi, et al.
Publicado: (2018)

MS‐275 potentiates the effect of YM‐155 in lung adenocarcinoma via survivin downregulation induced by miR‐138 and miR‐195
por: Luo, Bai‐Ling, et al.
Publicado: (2019)

Suppression of Rotenone-Treated Human Breast Cancer Stem Cell Survival Using Survivin Inhibitor YM155 is Associated to Oxidative Stress Modulation
por: Syahrani, Resda A, et al.
Publicado: (2020)

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
por: Kudchadkar, Ragini, et al.
Publicado: (2015)

YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
por: Na, Young-Soon, et al.
Publicado: (2012)

Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
por: Wani, Tasaduq H., et al.
Publicado: (2018)

YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells
por: Yan, Xiang, et al.
Publicado: (2017)

Prognostic and Clinicopathological Significance of Survivin in Colorectal Cancer: A Meta-Analysis
por: Krieg, Andreas, et al.
Publicado: (2013)

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
por: Aoyama, Yumiko, et al.
Publicado: (2012)

Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K(+) channels
por: ZHANG, SHUAI, et al.
Publicado: (2016)

Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G(2) checkpoint and suppression of homologous recombination repair
por: Qin, Qin, et al.
Publicado: (2014)

Video-Assisted Thoracoscopic Surgery with Bullectomy and Partial Pleurectomy versus Chest Tube Drainage for Treatment of Secondary Spontaneous Pneumothorax—A Retrospective Single-Center Analysis
por: Fung, Stephen, et al.
Publicado: (2022)

YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells
por: ONG, Siew Mei, et al.
Publicado: (2019)

Epigenetic Changes at the Birc5 Promoter Induced by YM155 in Synovial Sarcoma
por: Mika, Aleksander, et al.
Publicado: (2019)

YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity
por: Zhu, Congrui, et al.
Publicado: (2021)

YM155 exerts potent cytotoxic activity against quiescent (G(0)/G(1)) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1
por: Ookura, Miyuki, et al.
Publicado: (2017)

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway
por: Chang, Bill H, et al.
Publicado: (2015)

Deregulation of dicer and mir-155 expression in liposarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2015)

CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma
por: Werner, Thomas A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_heu6i56lcejvda3gv7utrsrii2